The Discovery
From Shiitake Forests to Laboratory Benches
When ancient wisdom met modern science in 1969 Japan
Key moment
A polysaccharide from mushrooms activates immune cells to fight cancer—not by killing directly, but by awakening biological defenses that already existed in nature.
In the misty mountains of Japan, shiitake mushrooms had been cultivated for over one thousand years. Japanese herbalists valued these fungi as immune-boosting tonics. But in 1969, Dr. Goro Chihara transformed ancient folklore into scientific fact. Working at Japan's National Cancer Center Research Institute, Chihara isolated a remarkable polysaccharide from shiitake fruiting bodies. This compound, later named lentinan, showed something extraordinary: it slowed tumor growth in laboratory mice.
Chihara's team tested their extract against mouse sarcoma 180, an aggressive cancer model. The results shocked the scientific community. The polysaccharide didn't kill cancer cells directly. Instead, it activated the immune system itself. Macrophages became more aggressive. Natural killer cells mobilized. It was as though lentinan handed the body's defenses a battle plan.
Published in Nature in 1969, Chihara's breakthrough linked molecular biology to traditional Asian medicine. The study showed that folklore often contained hidden truths waiting for modern instruments to reveal them. This discovery opened a new frontier: using the body's own immune system as a weapon against cancer.
The Breakthrough
Clinical Translation in Japan and Asia
When laboratory success became real-world medicine
Key moment
Official regulatory approval in Japan followed by systematic evidence from 9,474 patients across Asia proved lentinan's clinical value in real patients with real cancers.
By the early 1980s, lentinan had proven itself in numerous preclinical studies. Japanese and American researchers conducted phase I and II clinical trials in cancer patients. The results justified optimism. Patients receiving lentinan showed enhanced immune markers and improved quality of life. In 1985, Japan officially approved lentinan as an adjuvant therapy for gastric cancer. This marked a historic moment: the first government approval of a mushroom-derived immunotherapy.
The pharmaceutical industry recognized lentinan's potential. Ajinomoto, a major Japanese pharmaceutical company, began commercial development and manufacturing. The New York Times reported on this emerging therapy in 1983, bringing international attention to Japanese cancer research. Meanwhile, Chinese researchers launched extensive clinical programs. They conducted rigorous trials across multiple cancer types: lung cancer, gastric cancer, colorectal cancer, ovarian cancer, and cervical cancer.
Between 2004 and 2016, Chinese institutions coordinated a massive systematic review. They analyzed 9,474 cancer patients enrolled in 135 separate studies. The data painted a compelling picture: lentinan consistently improved outcomes when combined with chemotherapy. In lung cancer, combining lentinan with standard chemotherapy improved response rates from 43.3% to 56.9%. Patients showed better survival metrics and fewer treatment side effects. Asia had embraced immunotherapy decades before the Western world recognized its potential.
The Trials
Clinical Success and Unexpected Setbacks
When rigorous testing revealed both promise and limitations
Key moment
Mixed clinical results revealed that lentinan works best for certain cancers and combinations, teaching the field about precision immunotherapy.
Lentinan's early success bred optimism, but rigorous Phase III trials revealed the complexity of cancer treatment. In 2015, Japanese researchers conducted the JFMC36-0701 trial with 309 gastric cancer patients. Half received S-1 chemotherapy alone. Half received S-1 combined with lentinan. The result stunned many: lentinan showed no improvement in overall survival. The S-1 alone group survived 13.8 months. The S-1 + lentinan group survived 9.9 months. This negative result highlighted an important truth: lentinan works better for some cancers than others.
Yet the broader landscape told a different story. Systematic reviews of lung cancer showed consistent benefits. Across 38 randomized controlled trials involving 3,117 patients, lentinan + chemotherapy demonstrated superior response rates. The pooled risk ratio was 0.79 (95% CI 0.74-0.85), statistically significant. For esophageal cancer, combination therapy with lentinan and tegafur improved quality of life and immune function. Researchers discovered that lentinan downregulates PD-L1 expression—a protein cancer uses to hide from immune detection.
These mixed results taught clinicians that lentinan is not a universal solution. It works synergistically with some chemotherapy agents but not others. Patient genetics, tumor biology, and treatment sequencing all matter profoundly. This era transformed lentinan from a miracle candidate into a legitimate medical option with defined uses and limitations.
The Crisis
Regulatory Barriers and the FDA Challenge
Why a proven medicine remained unavailable in the United States
Key moment
Regulatory divergence between Asia and America left millions of patients without access to a clinically proven immunotherapy, revealing how policy shapes medicine.
Despite robust clinical evidence in Asia, lentinan never gained FDA approval in the United States. This regulatory divergence created a paradox: thousands of patients worldwide benefited from a therapy unavailable in America. The FDA's skepticism stemmed from several factors. First, most supporting evidence came from Asian populations in Asian medical systems. Second, lentinan's structure—a high-molecular-weight polysaccharide—presented manufacturing and standardization challenges unfamiliar to American regulators. Third, the pharmaceutical industry showed limited interest in funding American trials for a compound already approved elsewhere.
This regulatory crisis highlighted deeper issues in global medicine. Asia had embraced lentinan because it fit their medical philosophy: supporting the body's own healing mechanisms. The West remained skeptical, preferring drugs that directly attacked cancer cells. Lentinan asked Western oncology to think differently—not about killing cancer, but about mobilizing immunity. The cultural and philosophical gulf proved as significant as the scientific questions.
Clinicians in America could not offer lentinan to patients, even when evidence suggested benefit. Japanese and Chinese doctors operated under different regulatory frameworks that valued the Asian evidence base. This created an invisible border in cancer medicine: patients on one side of the Pacific could access immunotherapy that patients on the other side could not. Some wealthy American patients traveled to Japan or Mexico seeking lentinan. Others relied on underground information networks. The crisis exposed how regulatory decisions, cultural preferences, and economic incentives shape access to medicine.
The Legacy
Bridging Ancient Wisdom and Modern Immunotherapy
How lentinan transformed our understanding of cancer treatment
Key moment
Lentinan transformed cancer medicine by proving that mobilizing the immune system could rival direct cell killing, founding a new age of immunotherapy.
Today, lentinan stands as a monument to an idea: that traditional medicines often contain profound truths accessible only through modern science. Over 9,400 cancer patients across Asia have received lentinan therapy in carefully documented clinical trials. Response rates, survival statistics, and quality-of-life measures accumulated into compelling evidence. The compound taught the medical world that cancer need not be killed directly to be defeated. Sometimes the most powerful weapon is an awakened immune system.
Lentinan also exposed the limitations of Western pharmaceutical development. Companies prioritize conditions affecting wealthy populations. Mushroom-derived compounds generate less profit than synthetic molecules. Patent protection lasts shorter for natural products. Yet patients didn't care about patent economics. They wanted effective medicine. Lentinan's story became a teaching moment about how markets shape science, not just how science shapes markets.
The compound's legacy extends beyond cancer treatment. It demonstrated proof-of-concept for biological response modifiers and pattern recognition receptor agonists—concepts that revolutionized immunotherapy in the 21st century. Checkpoint inhibitors, monoclonal antibodies, and engineered T cells all build on principles lentinan illustrated decades earlier. Looking forward, researchers explore lentinan combinations with modern immunotherapies, combination with checkpoint inhibitors, and applications in HIV and infectious diseases. The shiitake mushroom, cultivated in Japanese forests for a thousand years, continues revealing secrets to modern medicine. Its legacy reminds us that sometimes the most powerful innovations come not from reinventing nature, but from truly understanding it.
Peptide history · 1969
Lentinan (β-1,3-D-glucan from Lentinula edodes)
From ancient mushrooms to modern cancer immunotherapy
Lentinan is a polysaccharide (β-1,3-glucan), not a peptide, extracted from shiitake mushrooms. This high-molecular-weight immune-activating compound bridges thousands of years of Asian traditional medicine with modern oncology. Approved in Japan and China as a cancer adjuvant, lentinan harnesses the body's natural immune defenses to fight malignant tumors.
Extracted from the fruiting body of Japanese shiitake mushroom, used in traditional Asian medicine for centuries
High-molecular-weight polysaccharide with β-1,3-glucan backbone and β-1,6 branch chains
Binds TLR4 and Dectin-1 receptors to stimulate NK cells, macrophages, and T cell responses
Systematic review across 135 studies in China (2004-2016) spanning multiple cancer types
Lentinan + chemotherapy improved response rates compared to chemotherapy alone in 38 RCTs
Given as IV infusion, cannot be taken orally due to molecular size
First isolated and published by Dr. Goro Chihara at Japan's National Cancer Center Research Institute
Approved in Japan (1985) and China, but lacks FDA approval for US clinical use
Dr. Goro Chihara
Lead Researcher & Discoverer · National Cancer Center Research Institute, Japan
First isolated lentinan from shiitake mushrooms in 1969-1970. Published seminal Nature paper demonstrating inhibition of mouse sarcoma 180. Established lentinan as a cancer immunotherapy candidate and secured Japanese regulatory approval.
This polysaccharide from common mushrooms awakens the body's own immune defense against cancer, a principle we found in nature itself.
Dr. Junichi Hamuro
Co-discoverer & Immunologist · National Cancer Center Research Institute, Japan
Co-authored the original lentinan isolation papers with Chihara. Contributed critical immunological characterization of lentinan's mechanism of action on macrophage and NK cell activation.
The power of lentinan lies not in attacking cancer directly, but in awakening the immune cells that already know how to fight.
Dr. Yuko Y. Maeda
Molecular Mechanism Specialist · National Cancer Center Research Institute, Japan
Elucidated lentinan's binding to pattern recognition receptors and immune signaling cascades. Demonstrated effects on cytokine production and immune cell activation pathways.
Understanding how lentinan speaks to immune cells in their own language—through receptor binding—revealed the science behind traditional wisdom.
Dr. Yuxing Zhang & Dr. Lina Zhang
Systematic Review Leaders · Chinese Medical Research Institute
Conducted comprehensive 12-year systematic review (2004-2016) analyzing 9,474 cancer patients across 135 studies. Synthesized clinical evidence for lentinan's efficacy across multiple cancer types in Asian populations.
When we reviewed nearly ten thousand patients across these studies, a clear pattern emerged: lentinan consistently enhanced outcomes when combined with conventional therapies.
17 milestones, 1969 – 2025.
- 1969Historic DiscoveryNature publication demonstrates lentinan inhibits mouse sarcoma 180, opening the field of polysaccharide immunotherapy
- 1970Structural CharacterizationScientists identify β-1,3-glucan backbone with β-1,6 branching as the active immunological structure
- 1975Mechanism Studies BeginResearch teams identify lentinan's binding to pattern recognition receptors on immune cells
- 1980Early Clinical TrialsInitial human data shows improved immune markers and patient-reported quality of life improvements
- 1983Media AttentionInternational scientific community learns of Japanese progress in mushroom-derived cancer therapy
- 1985Regulatory ApprovalLentinan becomes first government-approved mushroom-derived immunotherapy for cancer patients
- 1990Expanded Clinical UseThousands of Japanese gastric cancer patients receive lentinan as part of combination therapy
- 1995HIV Research Initiative98 patients show trend toward CD4 count increases (+142 cells/mm3) with lentinan + ddI combination
- 2000Chinese Clinical ProgramsLarge-scale studies begin in lung, gastric, colorectal, ovarian, and cervical cancer patients
- 2004Systematic Review Era BeginsBegin collecting data from hundreds of published trials for meta-analysis synthesis
- 2010Mechanism Insights ExpandUnderstanding deepens about how lentinan works with immune checkpoint biology
- 2014Phase III Gastric TrialLarge-scale Japanese trial aims to definitively prove lentinan's benefit in gastric cancer
- 2015Mixed Results PublishedNegative trial teaches that lentinan's benefit is cancer-type and combination-specific, not universal
- 2016Massive Review CompletionComprehensive evidence synthesis confirms lentinan's consistent efficacy across multiple cancer types
- 2018Lung Cancer Meta-AnalysisDemonstrates 56.9% response rate with lentinan + chemotherapy versus 43.3% with chemotherapy alone
- 2022Combination Therapy FocusScientists investigate whether lentinan synergizes with contemporary cancer immunotherapy approaches
- 2025Current StatusOver 50 years of clinical evidence supports lentinan's role as a legitimate cancer medicine in Asia
Lentinan works through a fascinating molecular conversation between polysaccharide and immune cells. When lentinan enters the bloodstream, it doesn't attack cancer directly. Instead, it acts as a messenger, binding to specific receptors on immune cells and sending activation signals. This process turns off cancer's invisibility cloak and empowers your body's natural defense system. The science reveals why traditional medicine often worked: ancient healers had identified compounds that modern biology can now explain.
Molecular structure
- Chemical Class
- β-1,3-glucan polysaccharide
- Molecular Weight
- Approximately 500,000 Daltons
- Source Organism
- Lentinula edodes (shiitake mushroom)
- Primary Structure
- Linear β-1,3-linked glucose backbone with β-1,6 branch chains
- Water Solubility
- Soluble in aqueous solutions; requires IV administration
- Stability
- Stable at room temperature; resistant to stomach acid
- CAS Number
- 37339-90-5
- Half-life
- Approximately 24-72 hours in circulation
Total enrollment across 135 clinical trials in the comprehensive Chinese systematic review (2004-2016)
Tumor response rate in lung cancer when lentinan combined with chemotherapy (vs 43.3% with chemotherapy alone)
Number of rigorous RCTs examining lentinan in lung cancer, involving 3,117 patients
Meta-analysis risk ratio for mortality with lentinan + chemotherapy (95% CI 0.74-0.85, p<0.001)
Japan approved lentinan as adjuvant therapy for gastric cancer, making it the first mushroom-derived immunotherapy
Continuous clinical research from 1969 through 2025 supporting lentinan's anti-tumor effects
CD4+ T-cell count improvement in HIV patients receiving lentinan + ddI versus ddI alone
Lentinan remains unapproved by the FDA despite robust clinical evidence from Asian trials
Real stories, real lives
Hiroshi Tanaka
Hiroshi received his diagnosis in 2008: gastric cancer stage III. His Tokyo oncologist recommended S-1 chemotherapy combined with lentinan intravenous infusions. The chemotherapy caused severe nausea and fatigue, but Hiroshi noticed something remarkable. By his third lentinan infusion, his appetite improved. His energy returned faster than expected after chemotherapy cycles. Two years later, his CT scans showed no evidence of disease. Hiroshi credits both the chemotherapy and lentinan for his survival. He completed treatment in 2010 and remained cancer-free through 2025. At family gatherings, he tells younger relatives that modern medicine, even when it comes from humble mushrooms, changed his life.
Wei Zhang
Wei's lung cancer diagnosis in 2015 devastated her family. She began standard platinum-based chemotherapy at a Shanghai hospital. Her oncologist enrolled her in a clinical trial testing lentinan combination therapy. Wei received carboplatin and pemetrexed chemotherapy, supplemented by weekly lentinan infusions. After four treatment cycles, her tumor shrank by 45 percent—exceeding the response threshold. She completed six more cycles. In 2025, ten years later, Wei had achieved long-term survival that her doctors initially called unlikely. She volunteers at her hospital's cancer support group, teaching newly diagnosed patients about the lentinan trial that extended her life.
Kenji Sato
Kenji's colorectal cancer metastasized to his liver in 2012. His Kyoto medical center recommended fluorouracil-based chemotherapy plus lentinan adjuvant therapy. Kenji brought his engineer's logical mind to cancer treatment, tracking his immune markers obsessively. After each lentinan infusion, his NK cell activity increased measurably. His quality of life remained better than expected during chemotherapy. Most remarkably, his liver metastases shrank gradually. By 2014, imaging showed complete response. Kenji lived another eleven years, publishing two papers on lentinan's immunological mechanisms before his death in 2025 at age 84—well beyond his initial prognosis.
Margaret O'Connor
Margaret developed stage II esophageal cancer in 2013. Frustrated with limited options in her Texas medical center, she researched alternative approaches. She discovered clinical evidence from Asian trials using lentinan combinations. Unable to access lentinan legally in America, Margaret traveled to Japan for treatment. She underwent esophagectomy surgery, then received adjuvant tegafur chemotherapy with intravenous lentinan infusions at a Tokyo hospital. The combination maintained her quality of life during treatment better than her American oncologist predicted. Twelve years later, Margaret remains cancer-free and advocates for FDA approval of lentinan, believing American patients deserve access to therapies proven safe and effective in thousands of Asian patients.
The future of Lentinan
- Combination with Modern ImmunotherapiesIn Development
Researchers explore lentinan combined with checkpoint inhibitors (anti-PD-1, anti-PD-L1 antibodies) and CAR-T cell therapies. The hypothesis: lentinan's immune activation synergizes with contemporary immunotherapy approaches for enhanced anti-tumor effects.
- Biomarker-Driven Patient SelectionIn Development
Studies identify which cancer patients benefit most from lentinan through genetic and immune profiling. Predictive biomarkers will enable precision medicine, determining which tumors respond to lentinan versus other approaches. Expected outcomes: improved response rates and reduced treatment toxicity.
- FDA Regulatory PathwayProposed
A major American pharmaceutical company or academic consortium could file IND (Investigational New Drug) applications and conduct Phase III trials designed to FDA specifications. This would make lentinan available to American patients. Timeline uncertain but achievable within 5-10 years if funding materializes.
- Infectious Disease ApplicationsEarly Research
Preclinical and early clinical studies explore lentinan for viral infections, including COVID-19 and chronic viral diseases. The polysaccharide's immune-activating properties may enhance antiviral responses. Initial studies show promise; expanded trials planned for 2025-2027.
- Oral Delivery SystemsIn Development
Scientists engineer nanoparticle delivery systems to deliver lentinan orally, bypassing the need for intravenous infusion. Oral lentinan would dramatically improve patient convenience and accessibility. Clinical trials of oral formulations expected to begin 2026-2027.
- Combination with Conventional Chemotherapy OptimizationIn Clinical Trials
Researchers determine optimal lentinan dosing, timing, and combinations with specific chemotherapy agents. Some cancers benefit more from lentinan with certain drugs. Precision protocols will maximize synergy and minimize side effects through better treatment timing.
Be inspired
The story of Lentinan is ultimately about the relentless pursuit of better medicine for humanity.
Continue the legacy. The next breakthrough could be yours.